演題抄録

ECCO/JSCO Joint Symposium

開催概要
開催回
第52回・2014年・横浜
 

Current status of chemoradiation therapy for esophageal cancer in Japan

演題番号 : ECJS-2

[筆頭演者]
Kitagawa Yuko:1 

1:Surgery, School of Medicine, Keio University

 

The Japan Clinical Oncology Group (JCOG) has conducted multicenter, multi-modality prospective clinical trials for the treatment of esophageal cancer for more than 30 years. JCOG9907 demonstrated significantly better overall survival after preoperative chemotherapy with 2 courses of cisplatin plus 5-fluorouracil followed by surgery, in comparison with postoperative chemotherapy for resectable cStageII/III thoracic squamous cell esophageal cancer. Although the current Japanese standard for resectable cStageII/III esophageal squamous cell carcinoma is preoperative chemotherapy with cisplatin plus 5-fluorouracil, subgroup analysis has shown survival benefit in cStage III to be insufficient. Although Japanese surgeons believe that the relatively acceptable local tumor control by transthoracic radical esophagectomy obviates the need for preoperative radiation therapy, development of more effective pre-operative treatment including CRT is required. Now, JCOG is conducting a 3-arm randomized controlled trial comparing preoperative chemo-radiation therapy with cisplatin plus 5-fluorouracil and preoperative chemotherapy with docetaxel in addition to cisplatin and 5-fluorouracil (DCF) to standard preoperative treatment with cisplatin plus 5-fluorouracil (JCOG1109). This study should be a significant milestone for surgical oncology in examining the possible additive efficacy and safety of preoperative chemo-radiation which is the current standard in the West. Furthermore, safety and efficacy of definitive chemoradiation using RTOG regimen followed by salvage treatment in cases it is required (JCOG0909) is now under investigation.

前へ戻る